Zymeworks Inc. Common Stock - Asset Resilience Ratio
Zymeworks Inc. Common Stock (ZYME) has an Asset Resilience Ratio of 47.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Zymeworks Inc. Common Stock's Asset Resilience Ratio has changed over time. Check Zymeworks Inc. Common Stock PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Zymeworks Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Zymeworks Inc. Common Stock stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $187.10 Million | 47.1% |
| Total Liquid Assets | $187.10 Million | 47.10% |
Asset Resilience Insights
- Very High Liquidity: Zymeworks Inc. Common Stock maintains exceptional liquid asset reserves at 47.10% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Zymeworks Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Zymeworks Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Zymeworks Inc. Common Stock (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Zymeworks Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 34.48% | $159.67 Million | $463.09 Million | -2.84pp |
| 2023-12-31 | 37.32% | $216.77 Million | $580.88 Million | +23.24pp |
| 2022-12-31 | 14.08% | $91.32 Million | $648.73 Million | +1.04pp |
| 2021-12-31 | 13.04% | $50.74 Million | $389.13 Million | -21.20pp |
| 2020-12-31 | 34.24% | $184.32 Million | $538.38 Million | -12.06pp |
| 2019-12-31 | 46.29% | $170.45 Million | $368.20 Million | -18.35pp |
| 2018-12-31 | 64.64% | $157.96 Million | $244.36 Million | +25.35pp |
| 2017-12-31 | 39.29% | $51.85 Million | $131.96 Million | +13.95pp |
| 2016-12-31 | 25.35% | $23.82 Million | $94.00 Million | +9.62pp |
| 2015-12-31 | 15.73% | $3.64 Million | $23.15 Million | -- |
About Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more